# A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors

> **NCT03518554** · PHASE1 · COMPLETED · sponsor: **Jacobio Pharmaceuticals Co., Ltd.** · enrollment: 38 (actual)

## Conditions studied

- Non-small Cell Lung Cancer
- Head and Neck Cancer
- Esophageal Cancer
- Other Metastatic Solid Tumors

## Interventions

- **DRUG:** JAB-3068

## Key facts

- **NCT ID:** NCT03518554
- **Lead sponsor:** Jacobio Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-23
- **Primary completion:** 2022-02-03
- **Final completion:** 2022-02-03
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2024-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03518554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03518554, "A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03518554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*